NUELIN SYRUP 80 mg15 ml

Land: Singapur

Sprache: Englisch

Quelle: HSA (Health Sciences Authority)

Wirkstoff:

THEOPHYLLINE

Verfügbar ab:

INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED

ATC-Code:

R03DA04

Dosierung:

80 mg/15 ml

Darreichungsform:

SYRUP

Zusammensetzung:

THEOPHYLLINE 80 mg/15 ml

Verabreichungsweg:

ORAL

Verschreibungstyp:

Prescription Only

Hergestellt von:

Ensign Laboratories Pty Ltd

Berechtigungsstatus:

ACTIVE

Berechtigungsdatum:

1989-05-09

Gebrauchsinformation

PLEASE NOTE: THIS IS A LOW RESOLUTION PDF & IS NOT TO BE USED AS
FINAL ARTWORK
Comments
VERSION 
0
5
10
20
30
40
50
60
70
80
95
100
Signatures
20.05.14 - New artwork build - Schee
DATE ....................................
20.05.14
LEAD MARKETING COUNTRY..............
Australia
ARTWORK SOFTWARE ..................
Illustrator CC
BRAND ...................................................
Nuelin
PRODUCT VARIANT .....................................
...................................................Nueline Syrup
CONSUMER UNIT CONTENT ..................
500mL
COMPONENT .......................
Label + Leaflet
PROJECT..........................................
XXXXX
FILE NAME..
69851_LT053901_Nuelin Syrup_500ml_Leaflet.ai
IMPORTANT: PDF’s are for viewing only.
They are NOT to be used for Final Artwork.
Colour
100%
BLACK
LT053901
69851
LT053901
303mm
60mm
Proposed annotated PI
PLEASE NOTE: THIS IS A LOW RESOLUTION PDF & IS NOT TO BE USED AS
FINAL ARTWORK
Comments
VERSION 
2
5
10
20
30
40
50
60
70
80
95
100
Signatures
16.05.14 - New artwork build - Schee
16.06.14 - Add Revision Date - Schee
24.06.14 - Add Australia - Schee
DATE ....................................
16.05.14
LEAD MARKETING COUNTRY..............
Australia
ARTWORK SOFTWARE ..................
Illustrator CC
BRAND ...................................................
Nuelin
PRODUCT VARIANT .....................................
....................................Nuelin Syrup Singapore
CONSUMER UNIT CONTENT ..................
500mL
COMPONENT .......................
Label + Leaflet
PROJECT..........................................
XXXXX
FILE NAME...
69772_LT053901_Nuelin Syrup SG_500ml_Label&Leaflet.ai
IMPORTANT: PDF’s are for viewing only.
They are NOT to be used for Final Artwork.
Colour
100%
PMS 285 C PMS 318C
BLACK
LT053901
69772
= 2.315 mm
LT053901
MANUFACTURED BY:
Ensign Laboratories Pty Ltd
490-500 Wellington Road,
Mulgrave, VIC 3170, Australia
Revision Date: Jun 2014
303mm
60mm

Fachinformation

Black
PMS
318 C
PMS
285 C
PMS
485 C
ARTWORK
COLOUR
100%
JOB NO. : JB-03070
UIC
: A7853
SKU
: 100539
A7853_NUELIN SYRUP 500ML
COMPONENT : FAF LABEL-LEAFLE
COUNTRY : SG
DIELINE REF: XXXXX
EMO: ENSIGN
PRINTER: Xxxxxx Xxxxxxxxxxxx
V1
G247 FILE NAME:
103284_A7853_NUELIN SYRUP
500ML_SG_LL_V1
13.03.24 - V0 - Artwork build - Sunny
14.03.24 - V1 - Amends - Yuki
Guide
Varnish
PLEASE NOTE
THIS HI RES PDF IS NOT TO BE USED AS FINAL ARTWORK
SUPPLIER INFORMATION MAY BE PRESENT ON THE
PACKAGING
EMO/PRINTING VENDOR:
PLEASE SHARE THE ARTWORK PDF TO PRINTER FOR
CHECKS ON:
• COLOURS - NO. OF COLOURS, SEQUENCE, CMYK/PMS
• TEXT - LINE THICKNESS, FONT SIZE
• DIELINE - SIZE, EYEMARK, PRINT DIRECTION
• CODING - SIZE, LOCATION, VFA, FORMAT BKG COLOUR
MOVING FORWARD WHEN POSSIBLE ANY ADDITONAL
INFORMATION AND TECHNICAL CHECK REQUIRED BY EMO
ON THE ARTWORK BEFORE APPROVING.
A7853
A7853
MANUFACTURED BY:
Ensign Laboratories Pty Ltd
490-500 Wellington Road,
Mulgrave, VIC 3170, Australia
Revision Date: March 2024
®
ADVERSE REACTIONS
The most common adverse reactions are gastric irritation,
nausea, vomiting, anorexia, epigastric pain, reactivation of
peptic ulcer, gastro-oesophageal reflux, haematemesis,
tachycardia, palpitation, headache, CNS stimulation, reflex
hyperexcitability, insomnia and tremor. Other possible
reactions include diarrhoea, extrasystoles, flushing,
hypotension, tachypnoea, potentiation of diuresis,
albuminuria, haematuria, rash, hyperglycaemia,
hypokalaemia, alopecia and inappropriate ADH secretion
(high dose). More serious signs of high serum levels
(usually above 30 µg/mL), such as cardiac arrhythmias
and convulsions, may appear rarely without prior warning.
DOSAGE AND ADMINISTRATION
Desirable therapeutic levels are considered to be between
10-20 µg/mL (55-110 µmol/L). Higher levels may produce
toxic effects. Toxic effects may also occur at therapeutic
levels. When maximum response is required, dose levels
should be individually titrated. Serum theophylline may be
monitored to confirm that levels are within t